LOY-002 Waitlist
Be First in Line When LOY-002 Launches
LOY-002 is a $250M-backed longevity drug program for senior dogs approaching FDA conditional approval in late 2026 or early 2027. Two of three FDA requirements are completed, with manufacturing submission in progress.
Quick eligibility check
Get an instant indication based on public LOY-002 study criteria, then join the readiness list.
What is LOY-002?
LOY-002 is being developed as a daily pill that targets metabolic aging pathways in senior dogs.
Current public target profile: dogs 10+ years old and 14+ lbs.
FDA timeline
- RXE accepted
- TAS accepted
- Manufacturing submission in progress
- Conditional approval possible late 2026 / early 2027
STAY clinical study
- 1,300 dogs enrolled
- 70 clinics participating
- ~4-year study design
How to prepare your dog